Factsheet and Information Brochure
Factsheet
Target Market
Costs and charges
Fund rules (164 kB)
Prospectus (1391 kB)
Periodic reports
Sustainability SFDR (929 kB)
Annual review (PF) (2875 kB)
Semi-annual report (PF) (199 kB)
Marketing material
Brief fund information
Summary SFDR (143 kB)
Handelsbanken Europa Selektiv (A1 NOK)
Legal name: Handelsbanken Europa Selektiv (A1 NOK)
Equity Fund Registered in Sweden (UCITS)
Bid
About risk
Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. Summary of investors' rights.
The fund is actively managed and invests in 16-35 equities over the long term that are issued by European companies and thereby has a currency exposure to these markets. Our focus is to construct a portfolio of high-quality companies with a variety of drivers and good outlooks and a reasonable valuation.
The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
Fund manager
David Cederberg Experience in the fund industry -. Portfolio Manager since 1 June 2023.
|
|
||
|---|---|---|---|
|
The risk indicator provides guidance on the risk level for this product relative to other financial products. It shows the likelihood that the product will decrease in value due to market performance. Risk level 1 represents a low risk and risk level 7 is a high risk.
|
|
30.06.2024
|
||
|---|---|---|---|
|
The rating shows which funds have historically posted the strongest performance in relation to risk. Ratings are denoted by a scale of one to five stars, with five as the highest rating. A fund must have a performance history of at least three years to receive a rating.
Read more about the fund's rating |
|
|
||
|---|---|---|---|
|
This fund promotes environmental and social characteristics through its investments but does not have sustainable investments as its objective. As a result, the fund takes into consideration the environment and climate, as well as human rights, employees’ rights and corruption. The fund is reported as an Article 8 fund pursuant to EU regulation on sustainability-related disclosures in the financial services sector (SFDR). |
|
31.05.2024
|
|||
|---|---|---|---|
|
The sustainability rating is developed by the fund information company Morningstar. The rating measures how well the fund's investee companies manage sustainability risks relative to other funds within the same global Morningstar category. If the fund has invested in government bonds issued by sovereign states, the respective country's sustainability risk is included in the calculation. The analyzed funds can receive a sustainability rating between 1 and 5 globes, with 5 as the highest rating. The fund complies with the UN Principles for Responsible Investments. |
Graph
Performance
| Rate 19.07.2024 | 1 week | 1 month | 3 months | 2024 | 1 year | 5 years | 10 years |
|---|---|---|---|---|---|---|---|
| 437.14 NOK | -2.25% | 2.33% | 4.09% | 11.18% | 16.80% | 71.22% | 129.48% |
Portfolio 11.07.2024
Portfolio manager comments — Q2 2024
Fund performance developed sideways during Q2. Major contributors included AstraZeneca, Infineon, Novo Nordisk and ASML. AstraZeneca’s new, explicit growth targets as well as positive clinical trial results provide increased confidence to an attractive growth profile over a number of years ahead, while the growth trend for Novo Nordisk continues to look strong. After a weak start to the year, Infineon has rebounded after the company provided additional communication about growth conditions and the ability to maintain its market position in China. ASML continues to post strength, driven by the approaching shift in technology in the semiconductor industry even though 2024 is a year with some cyclical weakness. The new holding in Rentokil has also contributed positively over a short time and we see conditions for the company to continue to perform strongly through streamlining and the successful integration of the Terminix acquisition going forward. Teleperformance also contributed to the fund when the equity rebounded in May, which led us to divest the remainder of the holding. French equities have subsequently lost ground in general due to the political uncertainty that has arisen in France. This resulted in the negative impact from Edenred in particular, and to some extent from Cap Gemini and Air Liquide.
Renewed concerns about further weak demand within biotechnology and medical technology weighed on the holdings in Tecan and Sartorius and, together with the French holdings, had a negative impact on the fund’s performance during the period. We believe that the high quality of the portfolio provides the conditions for a stronger performance going forward.
Portfolio distribution 30.06.2024
Geographic breakdown 30.06.2024
